Amino acids substitutions in σ1 and μ1 outer capsid proteins of a Vero cell-adapted
mammalian orthoreovirus are required for optimal virus binding and disassembly by Sandekian, Véronique & Lemay, Guy
Amino acids substitutions in σ1 and μ1 outer capsid proteins of a Vero cell-adapted 
mammalian orthoreovirus are required for optimal virus binding and disassembly
Véronique Sandekian and Guy Lemay*
Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Canada H3C 3J7
*Corresponding author:  Tel: +1 514 343 2422
Fax: +1 514 343 5701
Email address: guy.lemay@umontreal.ca (G. Lemay)
Département de microbiologie, infectiologie et immunologie
Pavillon Roger-Gaudry, Université de Montréal
P.O. Box 6128, Station Centre-ville
Montréal (Québec), Canada H3C 3J7
Running title: Reovirus adaptation to Vero cells























In a recent study, the serotype 3 Dearing strain of mammalian orthoreovirus was adapted to Vero cells; cells that exhibit a 
limited ability to support the early steps of reovirus uncoating and are unable to produce interferon as an antiviral response 
upon infection. The Vero cell-adapted virus (VeroAV) exhibits amino acids substitutions in both the σ1 and μ1 outer capsid 
proteins but no changes in the σ3 protein. Accordingly, the virus was shown not to behave as a classical uncoating mutant. 
In the present study, an increased ability of the virus to bind at the Vero cell surface was observed and is likely associated 
with an increased ability to bind onto cell-surface sialic acid residues. In addition, the kinetics of μ1 disassembly from the 
virions appears to be altered. The plasmid-based reverse genetics approach confirmed the importance of σ1 amino acids 
substitutions in VeroAV's ability to efficiently infect Vero cells, although μ1 co-adaptation appears necessary to optimize 
viral infection. This approach of combining in vitro selection of reoviruses with reverse genetics to identify pertinent amino 
acids substitutions appears promising in the context of eventual reovirus modification to increase its potential as an 
oncolytic virus.
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Mammalian orthoreoviruses, hereafter referred to as “reovirus”, are prototype members of the Orthoreovirus genus
in the Reoviridae family. These viruses are generally cytolytic as they kill and lyse infected cells in culture; this has been 
generally attributed to apoptosis (reviewed in: Clarke et al., 2005; Danthi et al., 2010), although both necrotic (Berger and 
Danthi, 2013) and autophagic (Thirukkumaran et al., 2013) cell death likely occurs in certain cell types.
In the last few years, there has been renewed interest in the study of these viruses, given their ability to 
discriminate between normal and transformed/cancer cells, specifically infecting and killing the latter and giving rise to the 
idea of using them as “oncolytic viruses”. This has led to numerous clinical studies as reviewed by others (Black and 
Morris, 2012; Clements et al., 2014; Harrington et al., 2010; Kelly et al., 2009; Maitra et al., 2012). Despite the fact that 
reoviruses are naturally oncolytic without prior genetic modifications, there is still a significant research effort ongoing to 
obtain novel virus variants better adapted to infect, replicate in, and kill cancer cells while sparing non-transformed cells 
(van den Hengel et al., 2013; Kim et al., 2011; Rudd and Lemay, 2005; Shmulevitz et al., 2012; van den Wollenberg et al., 
2009, 2012). One possible approach is to take advantage of novel viral variants that could be selected during establishment 
of viral persistence in different cell types.
Although reoviruses are considered to be essentially cytolytic, there have been numerous reports of persistence 
establishment with these viruses upon long-term cultivation of infected cells (reviewed in: Dermody, 1998). Since constant 
viral reinfection is needed to maintain the infected state, this has led to the identification of viral mutants, but few of those 
have been well characterized. In the most-studied L929 cell model, various amino acid substitutions were found in the viral 
σ1 protein and a single amino acid substitution in σ3 (Y354H); both proteins being part of the outer capsid of the virion. The
σ3-Y354H substitution was later shown to be most important for the ability of the virus to be maintained in persistently 
infected cells (Baer and Dermody, 1997; Ebert et al., 2001; Wetzel et al., 1997; Wilson et al., 2002). This amino acid 
substitution is located at the surface-exposed lobe of the σ3 outer capsid protein, thus increasing the protein's sensitivity to 
proteases and favoring viral uncoating under conditions where proteases are present in limiting amount (Baer and Dermody,
1997; Wetzel et al., 1997). In more recent studies, amino acid substitutions in σ3 were again observed in viruses recovered 
from Raji, HT1080 and CA46 cells, at positions consistent with an increased uncoating of these viruses; substitutions in σ1 
were also found in two of these viruses (Kim et al., 2011).
In the most recent study on reovirus persistence (Jabre et al., 2013), a novel variant of reovirus serotype 3 Dearing 





























(T3/Human/Ohio/Dearing/55), named Vero cell-adapted virus (VeroAV) was obtained by long-term culture of the virus on 
these cells that were previously shown to be somewhat resistant to a wild-type virus, due to their reduced ability to uncoat 
the virus (Golden et al., 2002). Prior treatment with chymotrypsin, uncoating virions to “infectious subviral particles” 
(ISVPs), significantly augmented infection by a wild-type virus while VeroAV exhibits an increased ability to infect Vero 
cells even in the absence of prior uncoating by chymotrypsin treatment. Surprisingly, VeroAV did not behave as an 
uncoating mutant, still showing normal sensitivity to inhibitors of lysosomal cathepsins, in contrast with uncoating mutants 
selected during viral persistence in L929 cells (Baer and Dermody, 1997; Wilson et al., 2002). Accordingly, VeroAV does 
not harbor amino acid substitutions in its σ3 protein (Jabre et al., 2013). However, two amino acids substitutions 
were found in each of the σ1 and μ1 outer capsid proteins (Jabre et al., 2013), at positions consistent 
with an altered binding to host cell surface or outer capsid disassembly (Reiter et al., 2011;  Zhang et 
al., 2005), but this was not further studied at the time.
The σ1 protein forms the surface-exposed spikes at the surface of the virion and binds to both sialic acid and the 
JAM receptor at the cell surface (Danthi et al., 2010; Dermody et al., 2013), σ1 is also retained in infectious subviral 
particles (ISVPs) that are generated by proteolytic cleavage of the outer capsid proteins; in fact, reovirus uncoating has been
shown to increase the binding of the resulting ISVPs to the cell surface (Chappell et al., 1998; Nibert et al., 1995). The 
proteolytic cleavage of the outer capsid, referred to as “uncoating”, takes place in endosomes following endocytosis of the 
viral particles or in the extracellular milieu where proteases are present. Uncoating can also be achieved in the laboratory by
chymotrypsin treatment of virions and this facilitates infection of certain cell types, such as the Vero cells used in the 
present study, that are inefficient in their ability to uncoat the virus (Golden et al., 2002). During uncoating, the σ3 protein is
first removed, followed by proteolytic cleavage of the μ1 protein, allowing the viral particles to cross the cellular or 
endosomal membrane (Danthi et al., 2010; Dermody et al., 2013). Together, the three outer capsid proteins σ1, σ3 and μ1, 
are thus critical in infectivity of the viral particles and initiation of the viral replication cycle.
In the present study, the importance of the σ1 and μ1 amino acid substitutions of VeroAV was thus further 
examined. The virus was first shown to exhibit an increased binding at the surface of Vero cells likely due to an increased 
binding to cell-surface sialic acid residues. An altered disassembly of its outer capsid, as evidenced by different kinetics of 
in vitro cleavage by chymotrypsin, was also observed. The novel plasmid-based reverse genetics system (Kobayashi et al., 
2007, 2010; reviewed in: Boehme et al., 2011; van den Hengel et al., 2013; Lemay, 2011) then allowed to establish that the 




























preferential infection of Vero cells is actually due to the σ1 amino acid substitutions, although the co-adaptation of μ1 
appears necessary to optimize viral infection. Altogether, these results indicate that the establishment of viral persistence can
select for different viral variants depending on the cell type. Combined with the analytical tool of reverse genetics, this 
could allow for the optimization of selective reovirus infection of different cell types.
2. Material and Methods
2.1. Cell lines and viruses
L929, HeLa and Vero cells were originally obtained from the American type culture collection (ATCC); the BHK 
cells stably expressing the T7 RNA polymerase have been described (Buchholz et al., 1999) and were a generous gift from 
the laboratory of Dr John Hiscott (Lady Davis Research Institute, Montréal, Canada). All cells were grown in minimal Eagle
medium (MEM) with 5% fetal bovine serum. Wild-type reovirus laboratory stock (T3DS) was derived from a pure plaque of
reovirus type 3 Dearing (T3/Human/Ohio/Dearing/55) and propagated at low multiplicity of infection on L929 cells. The 
original inoculum was obtained from the American Type Culture Collection (ATCC). Vero cell-adapted reovirus (VeroAV) 
was obtained following long-term culture of the wild-type virus on Vero cells (Jabre et al., 2013) and propagated on HeLa 
cells.
2.2. Antibodies
Hybridoma cell lines producing either anti-σ3 (4F2) or anti-μ1 (10F6) have been described (Virgin et al., 1991) and
were obtained from Dr Kevin Coombs (University of Manitoba). Cells were grown in MEM for suspension culture with 
10% fetal bovine serum, proline (20μg/ml) and β-mercaptoethanol (50μM) and antibodies were recovered, as previously 
described (Brochu-Lafontaine  and Lemay, 2012). The polyclonal antiserum directed against the carboxyl-terminal head 
domain of σ1 was produced originally in the laboratory of Dr. Terence Dermody (Vanderbilt University, Tennessee) and was
a generous gift from Dr. Earl Brown (University of Ottawa). The rabbit anti-tubulin antiserum was obtained from ICN 
Biomedicals Inc.




























2.3. Determination of virus titer
Virus titers were determined by TCID50 method on L929 cells in 96-wells plates (Danis and Lemay, 1993). For 
electron microscopy, infectious virus stocks were extracted once with Vertrel® XF (1,1,1,2,3,4,4,5,5,5-decafluoropentane; 
Miller-Stephenson Chemical company Inc.) (Mendez et al., 2000) to remove most cellular debris and mixed with latex 
beads at a known concentration. Processing of samples and microscopic observations were done at the INRS-Institut 
Armand Frappier (Laval, Québec) electron microscopy facilities.
2.4. Virus binding at the host-cell surface
Infectious viral particles at a MOI of 80 PFU/cell were allowed to bind onto the host-cell surface of L929 or Vero 
cells for one hour at 4ºC with occasional gentle agitation. Cells with bound virions were then extensively washed with cold 
medium and immediately frozen at -80ºC for virus titration. In some experiments, neuraminidase (from Clostridium 
perfringens, New England Biolabs) pretreatment was done at 37ºC at a concentration of 50 units/ml in tissue culture 
medium for one hour. Neuraminidase was then removed, cells were washed with medium, and binding of virions at 4ºC was
performed, as before.
2.5. In vitro cleavage of capsid proteins with chymotrypsin
Virions prepared by Vertrel extraction of viral stocks (propagated in the absence of serum) were incubated from 0 
to 30 minutes at 10 or 40 μg/ml concentrations of chymotrypsin at 37ºC or 28ºC. Reactions were stopped by addition of 2 
mM phenylmethylsulfonyl fluoride (PMSF) and samples were analyzed by immunoblotting using either the combination of 
anti-μ1 and anti-σ3 monoclonal antibodies or the anti-σ1 polyclonal antiserum.
2.6. Immunoblotting
Infected cells were recovered by scraping in a small volume of medium and processed for immunoblotting, as 
previously described (Brochu-Lafontaine and Lemay, 2012). Images were obtained using either autoradiography on Kodak 
BioMax Light films or on a Typhoon Trio™ imager (GE Healthcare Life Sciences).
2.7. Plasmid constructs
The plasmids separately harboring each of the cDNA corresponding to the 10 genes of reovirus serotype 3 Dearing 





























(T3DK), under the transcriptional control of the T7 promoter, were previously described (Kobayashi et al., 2007) and were a 
generous gift from the laboratory of Dr Terence Dermody (Vanderbilt University, Nashville, Tennessee). To obtain the virus 
mutant harboring the amino acids substitutions of VeroAV in the defined background of the reverse genetics system, a 
fragment of the gene encompassing all mutations was obtained by RT-PCR amplification on the viral VeroAV genome, 
essentially as previously described (Brochu-Lafontaine and Lemay, 2012; Jabre et al., 2013). PCR fragments were 
recovered and subcloned to replace the corresponding fragment in the M2 or S1 reverse genetics plasmid. A similar strategy 
was used to construct a wild-type plasmid corresponding to the initial wild-type laboratory virus stock (T3DS).
2.8. Rescue of infectious mutant viruses by reverse genetics
Small-scale preparations of endotoxin-free plasmid DNA, corresponding to the different M2 and S1 genes were 
column-purified as recommended by the manufacturer (Zyppy plasmid miniprep kit, Zymo Research). Recovery of 
infectious reovirus stocks by transfection of the baby hamster kidney (BHK) cell line constitutively expressing the T7 RNA 
polymerase (Buchholz et al., 1999) was done essentially as previously described (Brochu-Lafontaine and Lemay, 2012). 
The presence of the expected amino acid substitutions and absence of other mutations on the three genes encoding outer 
capsid proteins was verified by RT-PCR and sequencing of the corresponding fragment, as for the original VeroAV (Jabre et 
al., 2013).
2.9. Plaque assay
Plaque assays were performed on Vero cells in the presence of chymotrypsin (Sigma Type I-S from bovine 
pancreas) at 5μg/ml, as previously described (Brochu-Lafontaine and Lemay, 2012; Jabre et al., 2013).
3. Results
3.1. Binding of reovirus VeroAV at the cell surface
Considering the position of the amino acids substitutions on both σ1 and μ1 of VeroAV, it was previously suggested
that virus disassembly and/or binding could be affected by these changes (Jabre et al., 2013). This last point was first 
examined as a possible explanation for the increased ability of VeroAV to infect Vero cells.
Infectious virus stocks of either VeroAV or the original wild-type laboratory virus stock from which it was 





























originally derived were thus prepared by infection of HeLa cells; this wild-type virus will be referred to as type 3 Dearing, 
isolate Sandekian (T3DS) to distinguish it from other stocks of wild-type virus, as will be discussed later in the manuscript. 
VeroAV and T3DS virus stocks were first compared to determine if they exhibit a similar particle/infectious titer ratio. The 
presence of similar numbers of T3DS and VeroAV viral particles for the same viral titer was confirmed by quantitative 
electron microscopy using a latex bead standard (data not shown). Although somewhat variable from one preparation to 
another, the ratio of the number of virus particles to viral infectivity titer was approximately 100 particles/PFU for both 
viruses. This is, in fact, quite similar to previous reports by other groups (Bokiej and Dermody, 2012; Doyle et al., 2012; 
Frierson et al., 2012; Hand and Tamm, 1973; Mendez et al., 2000).
To directly determine their binding to the cell surface, virions were then adsorbed onto the cells In a preliminary
experiment, binding of the T3DS virus was shown to increase linearly at all MOI tested, up to 250 (data 
not shown). This is not surprising considering that binding assay are routinely performed at 50,000 
particles per cell by other investigators (for example Bokiej and Dermody, 2012). An intermediate MOI
of 80 was thus used thereafter to avoid saturation of the cellular receptors. In these conditions, T3DS 
bound to both L929 and Vero cells with essentially the same efficiency whereas the VeroAV virions showed more than 
fivefold increase in binding to Vero cells compared to the T3DS virions (Fig. 1). Although VeroAV virions also apparently 
bind slightly better to the L929 cell surface, this difference was not statistically significant. The data rather indicate that the 
increase in binding of VeroAV at the cell surface results from an adaption to binding preferentially onto these cells.
3.2. Binding of wild-type T3DS and VeroAV virions to sialic acids
Considering the position of the amino acid substitutions observed in σ1 of VeroAV (Table I), compared with wild-
type T3DS and wild-type reverse genetics virus (T3D-Kobayashi, T3DK), an increased binding of the virions to sialic acids at
the cell surface was postulated. Amino acid 198 is part of the sialic acid binding region of the protein, and is known to 
somehow contribute to the sialic binding property of the protein (Chappell et al., 1997; Dermody et al., 1990), although it 
does not appear to directly interact with the sugar moieties (Reiter et al., 2011).
In a preliminary experiment, the hemagglutination potential of VeroAV was examined as a first indication of 
binding to sialic acid (Chappell et al., 1997; Dermody et al., 1990). Semi-purified viral particles from either T3DS or VeroAV
were submitted to serial twofold dilutions and their ability to agglutinate bovine red blood cells was compared. At the 




























concentrations used, hemagglutination could not be detected with the semi-purified T3DS virions while, at the same protein 
concentration, hemagglutination was observed up to the 4th binary dilution with VeroAV. In this assay, when compared with 
cesium chloride-purified T3DS virions, the hemagglutination potential of VeroAV is thus at least 8-fold higher than that of 
T3DS (supplementary Fig. S1).
To further determine if the presence of sialic acid at the cell surface is involved in the increased binding of VeroAV 
to the surface of Vero cells, the cells were pre-treated with neuraminidase to remove cell surface sialic acids before virus 
binding. In preliminary experiments, the concentration of 50 units/ml appeared as optimal to see an 
effect on virus adsorption while minimizing host-cell toxicity (data not shown) this concentration was 
thus retained as experimental conditions. Although not considered statistically significant, an almost 
twofold increase in binding was found with T3DS; this is somewhat reminiscent of the situation 
observed with some “sialidase-insensitive” rotavirus strains (Haselhorst et al. 2009). This was not 
further investigated but could be due to increased accessibility of other cellular receptors, either protein
such as the JAM receptor or other glycans, after terminal sialic acid removal by neuraminidase. In 
contrast, there was an almost threefold decrease in binding for VeroAV under the same conditions  (Fig. 2). Altogether these 
results support the idea that increased binding of VeroAV at the surface of Vero cells depends on the presence of sialic acid 
residues at the cell surface.
3.3. Outer capsid disassembly of wild-type T3DS and VeroAV virions
Considering the position of amino acid substitutions on μ1, there is also a possibility that its cleavage and outer 
capsid disassembly could be affected, as discussed previously (Jabre et al., 2013), and could thus affect the differential 
infectivity of the virus in the presence or absence of prior chymotrypsin treatment. To directly examine this possibility, 
virions were treated with 10μg/ml chymotrypsin in vitro for different times. As expected, removal of σ3 was observed for 
both T3DS and VeroAV, although apparently less efficiently for VeroAV. However, a striking difference was observed for μ1 
that was gradually converted from μ1C to δ for T3DS while μ1C of VeroAV gradually disappeared without concomitant 
accumulation of δ protein (Fig. 3, upper panel).
This kinetics of T3DS disassembly is similar to that previously reported for serotype 1 Lang virus (T1L), while that 
of VeroAV resembles that of T3DK ( Madren et al., 2012; Sarkar and Danthi, 2010). This is not unexpected since the μ1 




























protein of T3DS harbors a valine at position 305, as in T1L, while an alanine is found in other isolates of T3D such as T3DK 
(Table I). This difference between T3DK and T1L is responsible for their different disassembly kinetics (Madren et al., 
2012). In contrast, although it harbors a valine at position 305, VeroAV behaves as T3DK; this is most likely due to the 
additional amino acid substitutions at positions 89 and/or 114 (Jabre et al., 2013). Interestingly, while we were completing 
this work, it has been further established that the loop comprising amino acids 72 to 96 of μ1 is involved in stability of the 
outer capsid and affects its disassembly upon protease treatment. It is especially striking that glutamic acid 89 was found to 
be the most critical amino acid in this phenotype (Sarkar and Danthi, 2013).
The amount of σ1 in the viral particles during gradual disassembly was also examined by immunoblotting. There 
was no apparent difference in the stability of the protein in the viral capsid during disassembly (Fig. 3, lower panel); 
however, a significantly higher amount of σ1 was found in VeroAV virions compared to  T3DS virions; as estimated by the 
ratio of σ1 to σ3 signal, there appears to be approximately three times more σ1 per viral particle for VeroAV compared to the
T3DS virions, raising the possibility that the amount of σ1 in the viral particle, in addition to a difference in affinity for 
sialic acids, could be responsible for increased virus binding at the cell surface.
3.4. Rescue of virus mutants using plasmid-based reverse genetics
To confirm that the amino acid substitutions in σ1 and μ1 are responsible for T3D adaptation to Vero cells and to 
explore whether amino acid substitutions on both proteins are required, the fragments encompassing the substitutions of 
VeroAV compared to T3DS were obtained by RT-PCR on the viral genomic dsRNA and used to substitute the homologous 
fragment in the corresponding gene of T3DK used for plasmid-based reverse genetics (Kobayashi et al., 2007).
These plasmid constructs could then be used to generate a mutant virus harboring the amino acid substitutions of 
VeroAV σ1 (protein referred hereafter as σ1-AV), including those differences between T3D S and T3DK that are also present 
in the same fragment. In parallel, the same procedure was applied to generate a plasmid harboring solely the three amino 
acid differences between T3DS and T3DK in this protein (proteins referred hereafter as σ1-S and σ1-K, respectively), in 
order to generate a control virus in a T3DK background for all other viral proteins. A similar procedure was used for the M2 
gene to introduce the fragment encompassing all amino acids changes on μ1 of VeroAV, including differences between 
T3DS and T3DK (protein hereafter referred to as μ1-AV). These two amino acid differences between T3D S and T3DK were 
introduced in a separate plasmid to generate a control virus harboring the μ1 protein of T3DS (hereafter referred to as μ1-S) 
in a wild-type T3DK background. The amino acid differences between T3DK, T3DS and VeroAV in both σ1 and μ1 proteins 





























are summarized in Table I.
The different plasmids were then used in the plasmid-based reverse genetics system to rescue viruses harboring 
amino acid substitutions in either σ1, μ1 or both, in an otherwise wild-type T3DK
 
background. All viruses were propagated 
before sequencing of the complete genes encoding σ1, σ3 and μ1 of the final virus stocks to confirm that they possessed the 
expected sequences.
For some viruses, the titers obtained upon viral propagation remained very low (Fig. 4).  
Interestingly, it appears that viruses produced with μ1-K had higher titers than those with either μ1-S or
μ1-AV except for the σ1-AV/μ1-AV combination. The worst combination was that of σ1-AV/μ1-S, 
strongly suggesting that μ1-S had to evolve concomitantly with σ1-AV during selection of VeroAV.
3.5. Infectivity of rescued viruses in Vero cells
The different viruses were then analyzed for their relative ability to infect Vero cells in the presence or absence of 
chymotrypsin in a single-cycle assay using immunoblotting. Two viruses, presenting poorly adapted protein combinations 
(σ1-K with μ1-AV and σ1-AV with μ1-S), and whose titers were reduced more than a thousandfold, were not examined.
As expected, viruses harboring either σ1-S/μ1-S or σ1-K/μ1-K wild-type combinations were poorly infectious on 
Vero cells in the absence of chymotrypsin while their infectivity was increased upon chymotrypsin treatment (Fig. 5), as 
with the original wild-type T3DS virus. The combination σ1-AV/μ1-AV resulted in a virus that was able to infect Vero cells 
independently of the presence of chymotrypsin, with even a small reduction in its presence, similar to the parental VeroAV. 
The two proteins are thus solely responsible for the adaptation of VeroAV to better infect Vero cells.
The σ1-AV protein VeroAV combined with μ1-K did confer by itself an ability to promote infection of Vero cells in
the absence of chymotrypsin. In contrast μ1-AV by itself had no effect when combined with σ1-S. Altogether, these data 
indicate that amino acid substitutions in σ1-AV are the primary determinants of the increased ability of VeroAV to infect 
Vero cells as virions. However, the nature of the μ1 protein is also of importance to optimize virus 
infection. While the σ1-AV/μ1-S virus could not be further studied, the σ1-AV/μ1-K virus was still 
partly dependent on prior chymotrypsin treatment to infect Vero cells (Fig. 5), indicating that μ1-AV 
contributes to overall viral fitness but may also affect the ability of σ1-AV to promote infection of Vero 
cells.




























In contrast to the predominant effect of σ1-AV on infection of Vero cells, the μ1-AV protein appears to be 
essentially responsible for increased sensitivity to chymotrypsin resulting in smaller plaques (Table II). As previously 
illustrated (Jabre et al., 2013), wild-type plaques are approximately 0.7 to 1 mm in diameter under the conditions used while
VeroAV plaques are mostly punctate and less than 0.2 mm in diameter. The 4 different combinations of T3DS and T3DK 
proteins did not yield plaque sizes that were significantly different from wild-type while the introduction of both σ1-AV and 
μ1-AV yielded plaques that were similar in size to that of the original VeroAV. However, the sole addition of μ1-AV to either
σ1-S or σ1-K resulted in a small-plaque phenotype suggesting that μ1-AV is responsible for this phenotype, as expected 
from its altered kinetics of chymotrypsin cleavage in vitro in the original VeroAV. The exact contribution of σ1-AV to this 
phenotype was more difficult to assess since it was not fully compatible with other μ1 proteins. However, despite a lower 
virus titer, plaques were still seen when σ1-AV was combined with μ1-K; their size was intermediate between that of T3D S 
and VeroAV plaques. The resistance σ1-AV to in vitro chymotrypsin digestion of the parental VeroAV (as shown in Fig. 3, 
lower panel) also supports the idea that it is not the principal determinant of chymotrypsin sensitivity or of altered virus 
disassembly.
3.6. Further characterization of rescued T3DK(σ1-AV/μ1-AV)
The phenotypic properties of the rescued virus harboring either the σ1 and μ1 protein of either T3DS or VeroAV in 
the T3DK background were then further examined. First, the effect of neuraminidase treatment on binding to Vero cells was 
examined by comparing the original T3DS and VeroAV with the rescued viruses, namely T3DK(σ1-AV/μ1-AV) and 
T3DK(σ1-S/μ1-S). The results confirmed that the presence of both σ1 and μ1 of VeroAV increased sensitivity to 
neuraminidase treatment up to a level similar to that of the original VeroAV (Fig.6, panel A). However, the increased 
binding of T3DS observed upon neuraminidase treatment was not observed with T3DK(σ1-S/μ1-S). This suggests that other 
differences between T3DS and T3DK do exist in other viral protein(s) and that they  indirectly affect the phenotype of σ1, as 
shown by others with amino acids substitutions in λ2 (Shmulevitz et al. 2012).
The kinetics of in vitro proteolytic uncoating of the same two rescued viruses was then 
examined and compared with that of the original T3DS and VeroAV, as in figure 3. This time, uncoating
was examined at both 37ºC and 28ºC, as described (Sarkar and Danthi, 2013). Removal of σ3 was less 
efficient for T3DK(σ1-AV/μ1-AV) than for T3DK(σ1-S/μ1-S), as with the original viruses (Fig. 6, panel 




























B), and this was better evidenced at the lower temperature; this indicates that the different kinetics of 
uncoating was maintained in the rescued viruses. More importantly, T3DK(σ1-S/μ1-S) showed an 
almost complete conversion of μ1C to δ at 37ºC, as expected, while in T3DK(σ1-AV/μ1-AV) there was 
a decline of μ1C without concomitant accumulation of δ. Again, the phenotype of  T3DK(σ1-AV/μ1-
AV) was thus essentially the same as that of the original VeroAV, in which δ is rapidly removed from 
ISVPs in the presence of proteases, and the wild-type T3DK(σ1-S/μ1-S) behaves as the original T3DS 
virus.
Finally, immunoblotting was performed on viral particles for some of these viruses whose titers 
were sufficiently high (Fig. 7). It was found that both the sequence of σ1 and μ1 affected the amount of 
virion-associated σ1. Virions corresponding to plasmid-rescued VeroAV T3DK(σ1-AV/μ1-AV) harbor 
more σ1 relative to σ3 than virions from plasmid-rescued T3DK(σ1-S/μ1-S), as observed with the 
original viruses presented on the right panel, as a control. This also corresponds to the previous 
observation at time 0 on Fig. 3. However, μ1-K was able to increase the amount of both σ1-S and σ1-
AV in the virion despite the fact that T3DK itself harbors a low amount of σ1. This again indicates that a
compatibility between  μ1 and σ1 is needed to optimize both the incorporation and function of σ1 in the
viral particles. However, there was no apparent relation between the number of σ1 molecules 
incorporated to the virion and either the ability to infect Vero cells (Fig. 5) or the replicative ability of 
these viruses on HeLa cells used for viral propagation (Fig. 4).
4. Discussion
As with most viruses, the replicative ability of mammalian reoviruses has been mostly examined in few cell types. 
In the last few years, renewed interest in oncolytic reovirus replication has led to the realization that the nature of the host 

























cells could restrict viral infection and lead, in return, to virus adaptation. In a previous work (Jabre et al., 2013), Vero cells 
were chosen as a model; these cells are also classically used to grow viruses for clinical applications (Berry et al., 1999; 
World Health Organization, 1987) and are deficient in interferon production (Desmyter et al., 1968; Emeny and Morgan, 
1979), thus facilitating large-scale production of interferon-sensitive viruses.
Surprisingly, virus persistence of reovirus in Vero cells did not give rise to a virus with an 
increased ability to be uncoated by lower amount of lysosomal cathepsins following viral endocytosis 
(Jabre et al., 2013). Accordingly, the σ3 protein, known as the major determinant of reovirus uncoating 
efficiency was left unaltered in VeroAV. However, the other two other outer capsid proteins, σ1 and μ1, 
respectively responsible for earlier step of virus binding at the host cell surface and later step of viral 
disassembly, were both exhibiting amino acids substitutions. Although the position of the substitutions 
lead to speculate about a possible alteration of virus binding and/or later disassembly steps (Jabre et al. 
2013), there was no experimental evidence to support this idea. In the present study, the virus was 
further studied by the new tools of plasmid-based reverse genetics in order to introduce the VeroAV 
amino acids substitutions in a wild-type virus background. These studies allowed to firmly establish 
that the  σ1 and μ1 amino acids substitutions are solely responsible for the ability of VeroAV to infect 
Vero cells in the absence of prior uncoating while giving rise to viruses that are more readily 
inactivated upon prolonged protease treatment. The increased ability to infect Vero cells was assigned 
essentially to an increased binding to sialic acids, as previously hypothesized (Jabre et al. 2013); 
however, a very interesting point is the apparent co-evolution between σ1 and μ1, suggesting that these 
two proteins need to be well-adapted to each other in order to optimize viral fitness.
If binding at the cell surface is critical to the efficient infection of Vero cells by VeroAV, it may appear surprising 
that the wild-type viruses can attach at similar levels on L929 and Vero cells; however, this is consistent with previous 
observations showing that binding of wild-type ISVPs is not increased compared to virions on Vero cells, despite the 
increase in infection (Golden et al., 2002). It is possible that the increased binding of VeroAV virions rather contributes to 
facilitate later entry steps, normally bypassed in ISVPs. Asparagine 198 was previously shown to be involved in σ1 binding 


























to sugars containing sialic acid (Chappell et al., 1997; Dermody et al., 1990; Reiter et al., 2011),  although crystallographic 
analysis failed to reveal a direct interaction between this amino acid residue and the sugar moieties (Reiter et al., 2011). In 
these studies, replacing the uncharged asparagine by an acidic amino acid (aspartic acid) was shown to preclude sialic acid 
binding. Reciprocally, in VeroAV, replacing asparagine by a basic amino acid (lysine) increases sialic acid binding. The 
observation that N198K was already found early in the process of viral adaptation (Jabre et al.,  2013) pleads in favor of its 
prominent role in the phenotype on Vero cells. However, the virus harboring solely this substitution was only partially able 
to bypass the restriction in Vero cells and still exhibited reduced infectivity (data not shown), indicating that later amino 
acids substitutions were required to achieve optimal infection as in VeroAV. Furthermore, it cannot be excluded that some 
other changes were later selected due to gradual virus-cell coevolution, as observed during reovirus persistence of various 
cell types (reviewed by: Dermody, 1998).
Unexpectedly, an approximately threefold increase in the amount of σ1 in VeroAV virions compared to the wild-
type was observed in the course of this work, and was shown to depend on both the nature of the σ1 and μ1 proteins. 
However, the increased amount of σ1 per se does not increase infectivity on Vero cells in the absence of adequate amino 
acid substitutions. It has been reported that some reovirus strains such as type 3 Dearing harbors an average of 
approximately 18 trimers of σ1 per particle while type 1 Lang harbors a full complement of 36 trimers (Coombs, 1998; 
Larson et al., 1994); considering the relative difficulty of precisely comparing these results, they appear consistent with a 
threefold increase in the amount of σ1 that was observed in VeroAV, rendering it similar to T1L with probably the highest 
possible number of σ1 trimers. It is interesting to note that reducing trimers to only three copies does not seem to affect 
infectivity, at least in L929 cells (Larson et al., 1994); the lack of effect on viral infectivity on Vero cells when the number 
of wild-type σ1 trimers increased is also consistent with this idea. Interestingly, an approximately 3-fold difference in σ1 
incorporation between two viral clones of reovirus type 3 Dearing was also recently reported (Nygaard et al., 2013) and 
attributed to an amino acid substitution in the virion-anchoring region of σ1. In VeroAV, the substitution at position 78 is 
outside the critical 28 amino acid amino-terminal anchoring region; although it cannot be excluded that this substitution in 
the adjacent region may influence incorporation (Leone et al., 1991). The exact significance of these variations in the 
amount of virion-incorporated σ1, if any, remains to be established but is likely due to differences in the structural stability 
of the capsid (Coombs, 1998). This is also supported by the observation that the loss of σ1 upon long-term storage of the 
virion at 4ºC is more drastic in strains that already have a lower amount of σ1 per virion (Nygaard et al., 2013).
Although the amino acid substitutions in μ1 do not appear to be directly involved in the ability of VeroAV to infect 





























Vero cells, the nature of the μ1 protein does affect viral replication per se and ability to infect Vero cells in the presence of 
the σ1 protein of VeroAV. The apparent co-evolution of σ1 and μ1 suggests that these two proteins need to be 
well-adapted to each other in order to optimize viral fitness. Similar observations were previously made in 
different contexts such as the determinants of apoptosis or neurovirulence (Clarke et al., 2001; Derrien et al., 2003; Hrdy et 
al., 1982; Rodgers et al., 1997; Tyler et al., 1996). These μ1 changes selected in VeroAV were probably necessary due to the 
nature of the μ1 protein in the initial wild-type virus (T3DS) since other μ1 sequences such as that of T3DK are also able, 
although not as efficiently, to accommodate the σ1 protein of VeroAV. As previously discussed (Jabre et al., 2013), the 
contact regions between μ1 in neighboring heterohexamers are similar to the contact regions between μ1 and the λ2 turret 
protein suggesting that amino acids at this interface, such as amino acid 89, could affect association or exposure of σ1 at the 
virion's surface (Liemann et al., 2002; Zhang et al., 2005; Middleton et al., 2007). The data presented herein give 
further support to the idea that these two proteins functionally interact.
 The presence of a valine at position 305 of μ1 in both T3DS and VeroAV also deserves to be further stressed; as 
previously noted, most isolates of mammalian reoviruses harbor a valine while an alanine is found in some virus stocks such
as T3DK. This amino acid was recently shown to affect autocleavage and viral disassembly (Madren et al., 2012; Sarkar and 
Danthi, 2010) and this difference could explain why the reverse genetics viruses harboring the μ1-K protein are able to 
promote infection in the absence of chymotrypsin when combined with the σ1-AV protein while the original μ1-S is not.  
Thus, there is clearly an influence of the original sequence of the virus on the final result obtained upon viral adaptation to a
given cell line. Although it is difficult to predict how a virus having a different μ1, such as T3DK, would have evolved under
the same conditions, it is likely that either σ1 alone or σ1 and μ1 would have adapted to Vero cells since T3DK virions infect 
these cells poorly.
In the present and previous manuscript (Jabre et al., 2013), Vero cells were used to demonstrate 
that it is possible to generate novel reoviruses that are adapted to different cell lines and that this does 
not solely rely on the ability of the virus to be uncoated, as in the classical L929 cells model. These 
proof of concept experiments suggest that it should be also possible to adapt the virus to different cell 
types in order to further optimize reovirus oncolytic ability. This idea has been previously suggested 
and, accordingly, novel viruses were found to be better adapted as oncolytic agents  (Kim et al., 2011; 



























Rudd et al., 2005; Shmulevitz et al., 2012; van den Wollenberg et al., 2012).  Viruses selected for their 
large-plaque phenotype using L929 cells, somewhat reminiscent of larger plaques formed by VeroAV 
on Vero cells in the absence of chymotrypsin, were shown to be better oncolytic viruses both in vitro 
and in animal models (Shmulevitz et al., 2012). A recent report (van den Wollenberg et al., 2012) also 
suggests that the ability to infect cells independently of the JAM receptor, possibly due to increased 
binding to sialic acids, could be a useful strategy against cancer cell types that express low levels of 
JAM and are thus relatively resistant to reovirus (van den Hengel et al., 2013; van den Wollenberg et 
al., 2009; van Houdt et al., 2008). Furthermore, a virus harboring a deletion of the JAM binding 
domain and binding solely onto cell surface sialic acids, was shown to be attenuated in nontransformed 
cells while retaining an oncolytic potential and exhibiting reduced host toxicity (Kim et al., 2011). 
Although there is no evidence yet that VeroAV has a superior oncolytic activity, it will thus be of 
interest to further study its ability to lyse tumor cells in tissue culture and eventually in animal models. 
Novel variant viruses, such as VeroAV, combined with the use of reverse genetics could allow the 
design of superior oncolytic agents while getting fundamental knowledge on the viral and cellular 
factors that determine a successful reovirus infection.
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Fig. 1. Virus binding at the cell surface. Inoculum of 8 X 108 TCID50 units of the original wild-type T3D (T3D
S) or of the 
derived Vero cell-adapted virus (VeroAV) were adsorbed at the surface of either L929 or Vero cells at a multiplicity of 
infection of 80 TCID50 units/cell. Following binding for one hour at 4ºC, cells were washed and bound virus was quantitated
by TCID50 titration on L929 cells. Results are presented as the mean of 5 (L929 cells) and 8 (Vero cells) independent 
binding experiments. Error bars represent standard error of the mean. P-value are based on a linear mixed-effects 
model using a random intercept grouped by replica. N.S.: not statistically significant, p > 0.05
Fig. 2. Effect of sialic acid removal on virus binding. Vero cells were left untreated or pre-treated with neuraminidase, 
before adsorption of 2 X 108 T3DS
 
or VeroAV virions and quantitation of bound virus, as in figure 1. Results are presented 
as the mean of four independent binding experiments with error bars representing standard error of the mean. P-value are 
based on a linear mixed-effects model using a random intercept grouped by replica. N.S.: not 
statistically significant, p > 0.05
Fig. 3. In vitro proteolytic cleavage of outer capsid proteins. Virions from infectious stocks of T3DS or VeroAV were 
extracted with Vertrel™ and treated for the indicated times at 37ºC with 10μg/ml chymotrypsin, as described in Methods. 
Reactions were stopped and proteins analyzed by immunoblotting using combination of anti-σ3 and anti-μ1 monoclonal 
antibodies (upper panel) or polyclonal antiserum against σ1 (lower panel). Positions of viral capsid proteins are indicated by
arrows.
Fig. 4. Replicative ability of rescued viruses. HeLa cells were infected at a MOI of 2 TCID 50 units/cell and virus stocks 
obtained by freeze-thaw lysate 48 hours post-infection. Virus titers were obtained by TCID50 on L929 cells. Results are 
























presented relative to the titer obtained with the T3DK(σ1-S/μ1-S) combination (7 X 107 PFU/ml) that was arbitrarily fixed to
1.
Fig. 5. Infection of Vero cells with rescued viruses. Viruses obtained by reverse genetics were used to infect Vero cells at a 
MOI of 2 in the absence or presence of chymotrypsin, as indicated; L929 cells were used as control. Proteins were 
recovered 24 hours post-infection and analyzed by immunoblotting using a combination of anti-σ3 and anti-μ1 monoclonal 
antibodies; positions of σ3 and μ1C are indicated. Lower panels present the same membrane that was re-probed with rabbit 
anti-tubulin antiserum indicating similar amount of proteins in each lane. Infections with the original T3DS and VeroAV are 
presented as controls.
Fig. 6. Phenotypic properties of rescued T3DK(σ1-AV/μ1-AV). Vero cells were left untreated or pre-treated with 
neuraminidase, as in figure 2, before adsorption of T3DK, VeroAV, rescued T3DK(σ1-S/μ1-S) or rescued T3DK(σ1-AV/μ1-
AV) at a multiplicity of infection of 80 TCID50 units/cell. Following binding for one hour at 4ºC, cells were washed and 
bound virus was quantitated by TCID50 titration on L929 cells, as in figure 1 and 2. The average effect of neuraminidase in 
two representative experiments is presented with error bars representing standard error of the mean (panel A). Virions from 
original T3DS and VeroAV (upper panel) or rescued T3DK(σ1-S/μ1-S) and T3DK(σ1-AV/μ1-AV) were extracted with 
Vertrel™ and treated for the indicated times at either 28ºC or 37ºC with chymotrypsin, a control reaction was left at 4ºC 
(panel B). Reactions were stopped and proteins analyzed by immunoblotting using combination of anti-σ3 and anti-μ1 
monoclonal antibodies. Positions of σ3 and μ1C and δ proteins are indicated by arrowheads.
Fig. 7. Amount of σ1 in virions of rescued viruses. Infectious virus stocks were extracted once with Vertrel and proteins 
analyzed by immunoblotting using a combination of anti-σ3 and anti-μ1 monoclonal antibodies (upper panels) or the anti-
σ1 polyclonal antiserum (lower panels); positions of σ3, μ1C and ơ1 are indicated. The original T3DS and VeroAV are 
presented as controls.




























Fig. S1. Hemagglutination potential of VeroAV compared to the T3DS. Virus stocks were extracted once with Vertrel to 
remove most of cellular debris and concentrated by ultrafiltration using Sartorius Vivaspin Turbo 15 centrifugal 
concentrators (molecular weight cutoff of 1 000 kDa). Serial binary dilution was done in tissue culture medium without 
serum, starting from an initial titer of 2 X 109 TCID50 units/ml. As a control, cesium-chloride purified virus was first diluted 
10-fold to reach an infectious titer of approximately 1010 TCID50 units/ml and similarly subjected to serial binary dilution. 
Fifty microliters of viruses at different dilutions were placed in round-bottom 96-wells microplates. Washed 10% bovine red
blood cells (Cedarlane) were diluted to 1.5% in tissue culture medium and 50μl were added to each well. Plates were 
examined and photographed after 3 hours of incubation at 4ºC.
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